GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from ...

London: GSK plc has concluded the acquisition of efimosfermin alfa from Boston Pharmaceuticals in a USD 2 billion ...

Efimosfermin showed promise in reducing liver fat and maintaining safety across multiple doses in adults with phenotypic MASH ...

GSK completes $2 billion acquisition of efimosfermin from Boston Pharmaceuticals: London, UK Wednesday, July 9, 2025, 09:00 Hrs [IST] GSK plc announced the completion of its previ ...

GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from Boston Pharmaceuticals in a $2bn deal. The transaction includes an ...

LONDON - GSK plc (LSE/NYSE:GSK) has completed its acquisition of efimosfermin alfa from Boston Pharmaceuticals, the company announced Monday. The deal, valued at up to $2 billion, includes an ...

GSK indicated that the addition of efimosfermin expands its pipeline for fibro-inflammatory diseases across liver, lung, and kidney. The company is also developing GSK’990, a siRNA therapeutic ...

LONDON - GSK plc (LSE/NYSE:LON: GSK) has completed its acquisition of efimosfermin alfa from Boston Pharmaceuticals, the company announced Monday. The deal, valued at up to $2 billion, includes an ...

Efimosfermin is a novel, once-monthly fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH ...

Kaivan Khavandi, Senior Vice President and Global Head of Respiratory, Immunology and Inflammation R&D at GSK, stated, “The close of our acquisition for efimosfermin alfa represents a significant ...